Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$474.06 USD

474.06
2,190,829

-2.94 (-0.62%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $474.20 +0.14 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Quality Systems (QSII) Beats on Earnings & Revenues in Q2

by Zacks Equity Research

Quality Systems' (QSII) solid total software, hardware revenues drove second-quarter earnings. A solid recurring revenue base is a key catalyst for the quarters to come.

    Zacks Equity Research

    Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2

    by Zacks Equity Research

    Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.

      Zacks Equity Research

      Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues

      by Zacks Equity Research

      Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.

        Zacks Equity Research

        Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales

        by Zacks Equity Research

        An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.

          Zacks Equity Research

          Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised

          by Zacks Equity Research

          Chemed (CHE) rides high on its Roto-Rooter business in Q3

            Zacks Equity Research

            ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines

            by Zacks Equity Research

            ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.

              Zacks Equity Research

              Stryker (SYK) Earnings and Revenues Beat Estimates in Q3

              by Zacks Equity Research

              Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.

                Zacks Equity Research

                Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y

                by Zacks Equity Research

                Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.

                  Zacks Equity Research

                  Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View

                  by Zacks Equity Research

                  Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.

                    Zacks Equity Research

                    GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down

                    by Zacks Equity Research

                    GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.

                      Zacks Equity Research

                      Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag

                      by Zacks Equity Research

                      Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.

                        Zacks Equity Research

                        Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up

                        by Zacks Equity Research

                        Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.

                          Zacks Equity Research

                          McKesson (MCK) Beats Earnings & Revenue Estimates in Q2

                          by Zacks Equity Research

                          McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.

                            Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Lockheed Martin, 3M, T-Mobile, Broadcom and Intuitive Surgical.

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Lockheed Martin, 3M, T-Mobile, Broadcom and Intuitive Surgical.

                              Zacks Equity Research

                              Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up

                              by Zacks Equity Research

                              On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.

                                Zacks Equity Research

                                LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance

                                by Zacks Equity Research

                                Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.

                                  Zacks Equity Research

                                  Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View

                                  by Zacks Equity Research

                                  Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.

                                    Zacks Equity Research

                                    Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up

                                    by Zacks Equity Research

                                    Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.

                                      Zacks Equity Research

                                      NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut

                                      by Zacks Equity Research

                                      NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.

                                        Zacks Equity Research

                                        Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates

                                        by Zacks Equity Research

                                        Accuray (ARAY) rides high on its product and service segments in Q1.

                                          Zacks Equity Research

                                          Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance

                                          by Zacks Equity Research

                                          Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.

                                            Zacks Equity Research

                                            Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues

                                            by Zacks Equity Research

                                            Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.

                                              Zacks Equity Research

                                              Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact

                                              by Zacks Equity Research

                                              Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.

                                                Zacks Equity Research

                                                Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues

                                                by Zacks Equity Research

                                                Intuitive Surgical (ISRG) posted solid numbers in the third quarter, courtesy of rising customer adoption of procedures and growth in system placements.

                                                  Tracey Ryniec headshot

                                                  This Week's Amazing Earnings Charts

                                                  by Tracey Ryniec

                                                  Don't look now, but these 5 companies have some of the best earnings track records and charts this week.